Logo

BridgeBio Entered into a Collaboration with Helsinn to Co-Develop and Co-Commercialize GPX4 Program for Multiple Cancer

Share this
BridgeBio Entered into a Collaboration with Helsinn to Co-Develop and Co-Commercialize GPX4 Program for Multiple Cancer

BridgeBio Entered into a Collaboration with Helsinn to Co-Develop and Co-Commercialize GPX4 Program for Multiple Cancer

Shots:

  • The collaboration builds on the March 2021 license agreement for $2.45B to develop BridgeBio’s infigratinib (FGFR inhibitor) in oncology indications
  • Under the non-exclusive agreement, BridgeBio is eligible to receive a profit share on US sales along with royalties on Ex-US sales. The companies get the option to collaborate on preclinical oncology programs & will share global development responsibilities for each program
  • The agreement will utilize BridgeBio’s drug discovery expertise and Helsinn’s clinical development and commercial capabilities to develop & commercialize the GPX4 program for cancer. Helsinn to get exclusive manufacturing and commercial rights to the programs

| Ref: BridgeBio | Image: LinkedIn


Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions